Skip to main content

Outlook Therapeutics, Inc.

OTLK
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001649989

In the last 90 days, Outlook Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 68 institutions reported holding it in 13F filings for Q2 2026, worth $32.2M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Outlook Therapeutics, Inc. changed between Q2 2025 and Q3 2025.

All holders in Q3 2025All holders in Q2 2025

13F holders of OTLK: Q2 2025 compared with Q3 2025
MeasureQ2 2025Q3 2025Change
Holders6755−12
Shares5.98M4.08M−1.90M (−31.7%)
Value$9.57M$4.33M−$5.24M (−54.8%)

New holders (7)

Institutions that held Outlook Therapeutics, Inc. at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to OTLK in Q3 2025
InstitutionSharesValue% of portfolio
Simplex Trading, LLC89,241$94.0K0.00%
Two Sigma Securities, LLC35,664$37.8K0.01%
Flower City Capital20,000$21.2K0.01%
Two Sigma Investments, LP11,356$12.0K0.00%
Jones Financial Companies LLLP2,500$2.42K0.00%
Wealthspire Advisors, LLC300$3180.00%
Tradewinds Capital Management, LLC100$1060.00%

Sold out (19)

Institutions that held Outlook Therapeutics, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.